Immune Design Corp.
IMDZ
IMDZ was delisted on the 1st of April, 2019.
60 hedge funds and large institutions have $102M invested in Immune Design Corp. in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 11 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
24% more capital invested
Capital invested by funds: $82.3M → $102M (+$19.7M)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding
Funds holding: 60 → 60 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$16.1M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$12.6M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$8.77M |
| 4 |
NC
Nexthera Capital
New York
|
+$1.61M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$9.39M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.69M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$838K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$474K |
| 5 |
SIM
Spark Investment Management
New York
|
-$339K |
IMDZ Hedge Fund Activity: Q3 2016 in Review
60 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Immune Design Corp. (IMDZ) for Q3 2016, worth a combined $102M — up 24% from $82.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new IMDZ positions and 11 closed out — a net gain of 1 holder — while 21 added to existing stakes and 14 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $16.1M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $9.39M sold.
- 60 institutional investors held Immune Design Corp. (IMDZ) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $102M of Immune Design Corp. stock for Q3 2016, up 24% quarter-over-quarter.
- 12 funds opened new Immune Design Corp. positions in Q3 2016 and 11 closed out, a net change of +1 holder.
- The largest Immune Design Corp. buyer in Q3 2016 was Versant Venture Management, an estimated $16.1M added.
- The largest Immune Design Corp. seller in Q3 2016 was Pictet Asset Management (UK), an estimated $9.39M sold.
Based on aggregated 13F filings for Q3 2016.